Product Pathways - Tyrosine Kinase / Adaptors
Met (L6E7) Mouse mAb #8741
|8741S||100 µl (200 tests)||---||In Stock||---|
|8741||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Applications Key: IF-IC=Immunofluorescence (Immunocytochemistry), F=Flow Cytometry
Specificity / Sensitivity
Met (L6E7) Mouse mAb recognizes endogenous levels of total Met protein.
Source / Purification
Monoclonal antibody is produced by immunizing animals with mammalian cells expressing an amino terminal fragment of c-Met protein.
Flow cytometric analysis of unpermeabilized Ramos (red), T-47D (blue), HCT 116 (orange), and MKN-45 (green) cells using Met (L6E7) Mouse mAb.
Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).
- Cooper, C.S. et al. (1984) Nature 311, 29-33.
- Bottaro, D.P. et al. (1991) Science 251, 802-4.
- Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
- Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
- Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
- Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
- Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3135 Phospho-Met (Tyr1003) (13D11) Rabbit mAb
- 3077 Phospho-Met (Tyr1234/1235) (D26) XP® Rabbit mAb
- 4033 Phospho-Met (Tyr1234/1235) (D26) XP® Rabbit mAb (Biotinylated)
- 4091 Phospho-Met (Tyr1234/1235) (D26) XP® Rabbit mAb (Sepharose Bead Conjugate)
- 3129 Phospho-Met (Tyr1234/1235) (3D7) Rabbit mAb
- 3126 Phospho-Met (Tyr1234/1235) Antibody
- 3133 Phospho-Met (Tyr1349) (130H2) Rabbit mAb
- 3121 Phospho-Met (Tyr1349) Antibody
- 8198 Met (D1C2) XP® Rabbit mAb
- 8494 Met (D1C2) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate)
- 8041 Met (D1C2) XP® Rabbit mAb (Biotinylated)
- 5631 Met (11C4) Mouse mAb (Flow Specific)
- 3127 Met (25H2) Mouse mAb
- 3148 Met (L41G3) Mouse mAb
- 5086 Met (L41G3) Mouse mAb (Biotinylated)
- 4560 Met Antibody
For Research Use Only. Not For Use In Diagnostic Procedures.
DRAQ5® is a registered trademark of Biostatus Limited.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.